Annual Total Long Term Liabilities
$2.01 M
-$847.38 M-99.76%
December 31, 2023
Summary
- As of February 7, 2025, NMRA annual total long term liabilities is $2.01 million, with the most recent change of -$847.38 million (-99.76%) on December 31, 2023.
- During the last 3 years, NMRA annual total long term liabilities has fallen by -$280.95 million (-99.29%).
- NMRA annual total long term liabilities is now -99.76% below its all-time high of $849.39 million, reached on December 31, 2022.
Performance
NMRA Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$55.00 K
-$34.00 K-38.20%
September 30, 2024
Summary
- As of February 7, 2025, NMRA quarterly total long term liabilities is $55.00 thousand, with the most recent change of -$34.00 thousand (-38.20%) on September 30, 2024.
- Over the past year, NMRA quarterly long term liabilities has dropped by -$1.00 million (-94.81%).
- NMRA quarterly long term liabilities is now -99.99% below its all-time high of $849.39 million, reached on December 31, 2022.
Performance
NMRA Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
NMRA Long Term Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -99.8% | -94.8% |
3 y3 years | -99.3% | -100.0% |
5 y5 years | +100.0% | -100.0% |
NMRA Long Term Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -99.8% | at low | -100.0% | at low |
5 y | 5-year | -99.8% | -100.0% | -100.0% | at low |
alltime | all time | -99.8% | -100.0% | -100.0% | at low |
Neumora Therapeutics Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $55.00 K(-38.2%) |
Jun 2024 | - | $89.00 K(-91.6%) |
Mar 2024 | - | $1.06 M(-47.2%) |
Dec 2023 | $2.01 M(-99.8%) | $2.01 M(-31.5%) |
Sep 2023 | - | $2.93 M(-99.7%) |
Jun 2023 | - | $847.40 M(-0.2%) |
Dec 2022 | $849.39 M | $849.39 M(+15.5%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2022 | - | $735.43 M(+0.6%) |
Mar 2022 | - | $730.93 M(-0.0%) |
Dec 2021 | $731.24 M(+158.4%) | - |
Dec 2021 | - | $731.24 M(-0.0%) |
Sep 2021 | - | $731.47 M(+158.5%) |
Dec 2020 | $282.96 M(>+9900.0%) | $282.96 M |
Dec 2019 | $0.00 | - |
FAQ
- What is Neumora Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Neumora Therapeutics?
- What is Neumora Therapeutics annual total long term liabilities year-on-year change?
- What is Neumora Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly long term liabilities year-on-year change?
What is Neumora Therapeutics annual total long term liabilities?
The current annual total long term liabilities of NMRA is $2.01 M
What is the all time high annual total long term liabilities for Neumora Therapeutics?
Neumora Therapeutics all-time high annual total long term liabilities is $849.39 M
What is Neumora Therapeutics annual total long term liabilities year-on-year change?
Over the past year, NMRA annual total long term liabilities has changed by -$847.38 M (-99.76%)
What is Neumora Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of NMRA is $55.00 K
What is the all time high quarterly long term liabilities for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly total long term liabilities is $849.39 M
What is Neumora Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, NMRA quarterly total long term liabilities has changed by -$1.00 M (-94.81%)